We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

93 hedge funds and large institutions have $627M invested in Coherus Oncology in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 44 increasing their positions, 24 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 24

13.09% more ownership

Funds ownership: 78.28% → 91.37% (+13%)

9% more capital invested

Capital invested by funds: $576M → $627M (+$50.5M)

12% less funds holding

Funds holding: 106 → 93 (-13)

26% less call options, than puts

Call options by funds: $1.43M | Put options by funds: $1.92M

57% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 21

Holders
93
Holders Change
-13
Holders Change %
-12.26%
% of All Funds
2.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
44
Reduced
24
Closed
21
Calls
$1.43M
Puts
$1.92M
Net Calls
-$491K
Net Calls Change
-$3.57M

Top Buyers

Rank Fund Capital Flow
1
Temasek Holdings
Temasek Holdings
Singapore
+$86.7M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$18.3M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$6.98M
4
State Street
State Street
Massachusetts
+$6.08M
5
JP Morgan Chase
JP Morgan Chase
New York
+$4.76M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$25.9M
2
CAM
Cormorant Asset Management
Massachusetts
-$8.9M
3
CC
Carlson Capital
Texas
-$3.84M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$3.24M
5
CCI
Columbus Circle Investors
-$2.73M
Name Holding Trade Value Shares
Change 		Change in
Stake
ARTA
76
A.R.T. Advisors
New York
$174K +$173K +13,099 New
LTFS
77
Ladenburg Thalmann Financial Services
Florida
$168K +$139K +10,491 +497%
SG Americas Securities
78
SG Americas Securities
New York
$156K +$59K +4,461 +62%
Legal & General Group
79
Legal & General Group
United Kingdom
$139K +$13.8K +1,046 +11%
Simplex Trading
80
Simplex Trading
Illinois
$135K +$134K +10,152 New
Barclays
81
Barclays
United Kingdom
$115K -$172K -13,008 -60%
Royal Bank of Canada
82
Royal Bank of Canada
Ontario, Canada
$95K +$49.3K +3,724 +110%
BNP Paribas Financial Markets
83
BNP Paribas Financial Markets
France
$49.2K -$3.36K -254 -6%
AIP
84
Ameritas Investment Partners
Nebraska
$48K – – –
Canada Life
85
Canada Life
Manitoba, Canada
$46K – – –
IUHSA
86
Itau Unibanco Holding S.A.
Brazil
$42K +$13.2K +995 New
TRCT
87
Tower Research Capital (TRC)
New York
$39K +$33K +2,492 +623%
Federated Hermes
88
Federated Hermes
Pennsylvania
$20K +$19.4K +1,469 New
FPFS
89
First Personal Financial Services
North Carolina
$20K +$19.5K +1,476 New
Parallax Volatility Advisers
90
Parallax Volatility Advisers
California
$14K +$3.84K +290 +40%
Zurich Cantonal Bank
91
Zurich Cantonal Bank
Switzerland
$8K – – –
SEI Investments
92
SEI Investments
Pennsylvania
$1K +$503 +38 New
PHS
93
PFM Health Sciences
California
– -$25.9M -1,802,611 Closed
CAM
94
Cormorant Asset Management
Massachusetts
– -$8.9M -620,300 Closed
Lord, Abbett & Co
95
Lord, Abbett & Co
New Jersey
– -$3.24M -225,592 Closed
CCI
96
Columbus Circle Investors
– -$2.73M -189,933 Closed
Principal Financial Group
97
Principal Financial Group
Iowa
– -$2.02M -140,390 Closed
Bank of Montreal
98
Bank of Montreal
Ontario, Canada
– -$1.34M -93,550 Closed
Susquehanna International Group
99
Susquehanna International Group
Pennsylvania
– -$797K -60,247 Closed
Lazard Asset Management
100
Lazard Asset Management
New York
– -$704K -49,100 Closed
1 2 3
4
5

CHRS Hedge Fund Activity: Q3 2017 in Review

93 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2017, worth a combined $627M — up 8.8% from $576M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of CHRS and 9 opened new positions — a net loss of 12 holders — while 24 trimmed existing stakes and 44 added.

The largest buyer was Temasek Holdings, opening a new position worth an estimated $86.7M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $25.9M sold.

  • 93 institutional investors held Coherus Oncology (CHRS) as of Q3 2017, down from 106 in Q2 2017.
  • Funds reported $627M of Coherus Oncology stock for Q3 2017, up 8.8% quarter-over-quarter.
  • 9 funds opened new Coherus Oncology positions in Q3 2017 and 21 closed out, a net change of -12 holders.
  • The largest Coherus Oncology buyer in Q3 2017 was Temasek Holdings, an estimated $86.7M added.
  • The largest Coherus Oncology seller in Q3 2017 was PFM Health Sciences, an estimated $25.9M sold.

Based on aggregated 13F filings for Q3 2017.